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Abstract: Pancreatic cancer, mostly pancreatic ductal adenocarcinoma (PDAC), is one of the most
lethal cancer types, with an estimated 44,330 death in 2018 in the US alone. While targeted therapies
and immune checkpoint inhibitors have significantly improved treatment options for patients
with lung cancer and renal cell carcinomas, little progress has been made in pancreatic cancer,
with a dismal 5-year survival rate currently at ~8%. Upon diagnosis, the majority of pancreatic
cancer cases (~80%) are already metastatic. Thus, identifying ways to reduce pancreatic cancer
metastasis is an unmet medical need. Furthermore, pancreatic cancer is notorious resistant to
chemotherapy. While Kirsten RAt Sarcoma virus oncogene (K-RAS) mutation is the major driver for
pancreatic cancer, specific inhibition of RAS signaling has been very challenging, and combination
therapy is thought to be promising. In this study, we report that combination of hedgehog
(Hh) and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) signaling
inhibitors reduces pancreatic cancer metastasis in mouse models. In mouse models of pancreatic
cancer metastasis using human pancreatic cancer cells, we found that Hh target gene Gli1 is
up-regulated during pancreatic cancer metastasis. Specific inhibition of smoothened signaling
significantly altered the gene expression profile of the tumor microenvironment but had no significant
effects on cancer metastasis. By combining Hh signaling inhibitor BMS833923 with RAS downstream
MEK signaling inhibitor AZD6244, we observed reduced number of metastatic nodules in several
mouse models for pancreatic cancer metastasis. These two inhibitors also decreased cell proliferation
significantly and reduced CD45+ cells (particularly Ly6G+CD11b+ cells). We demonstrated that
depleting Ly6G+ CD11b+ cells is sufficient to reduce cancer cell proliferation and the number of
metastatic nodules. In vitro, Ly6G+ CD11b+ cells can stimulate cancer cell proliferation, and this effect
is sensitive to MEK and Hh inhibition. Our studies may help design novel therapeutic strategies to
mitigate pancreatic cancer metastasis.
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1. Introduction
Pancreatic cancer is the most deadly human cancer type [1]. Pancreatic cancer, now the third
leading cause of cancer-related death, is predicted to become the second cause of cancer-related death
by 2030 in the US (with lung cancer still the number one cause) [2]. Gemcitabine, approved to treat
pancreatic cancer in 1997, continues to be the first line chemotherapy drug [3]. While most targeted and
immune therapeutic strategies failed to benefit the patients, there are only two new strategies leading
to slightly better patient survival, namely bi-weekly bolus plus infusional fluorouracil, leucovorin,
irinotecan, and oxaliplatin regimen (Folfirinox) [4] and gemcitabine with Nab paclitaxel [5]. Thus,
there is an urgent medical need to establish novel strategies to treat pancreatic cancer.
Previous studies show different roles of hedgehog signaling in pancreatic cancer. On the one
hand, it is known that hedgehog (Hh) signaling is active during pancreatic cancer development and
progression, and inhibition of Hh signaling allows better drug penetration in the primary tumor and
reduces pancreatic cancer development [6–8]. Genetically, inactivation of Gli transcription factors slows
down tumor development and progression of pancreatic cancer in the KrasLSL.G12D/+; p53R172H/+;
PdxCretg/+ (KPC)-based mouse models. In KPC mouse models, Smoothened inhibitor IPI-926 was
shown to reduce pancreatic cancer development [6]. On the other hand, genetic removal of Shh in
pancreas or depletion of fibroblasts promotes pancreatic cancer development and progression in
KPC-based mouse model [9,10]. These seemly contradicted results may be explained by the fact
that both canonical and non-canonical Hh signaling exist during pancreatic cancer development and
progression, and non-canonical Hh signaling is not affected by smoothened inhibitors. Failure of
Smoothened inhibitors in clinical trials in patients with metastasis further confirms that inhibition of
canonical Hh signaling alone is not sufficient to reduce pancreatic cancer progression, and indicates
that paracrine Shh signaling has a very different role from Hh signaling in the cancer cells. Up to
now, there are no reported combined therapeutics with smoothened inhibitor and another targeted
therapeutic agent in cancer models, and this possibility may help re-initiate more clinical trials for
novel cancer treatment.
K-RAS mutation is the most common genetic alteration in pancreatic ductal adenocarcinoma
(PDAC) [11–13], and several mouse models of pancreatic cancer have been developed through inclusion
of the most common K-RAS gene mutation K-RASG12D [14–17]. Currently, there are no specific
therapeutic inhibitors for K-RAS although a number of inhibitors targeting RAS downstream effectors,
such as MEK and phosphoinositide 3 kinase (PI3K), are available [11].
In this report, we tested the possibility that combination of smoothened inhibitor with an inhibitor
targeting one of the K-RAS downstream effectors may be effective in reducing pancreatic cancer
metastasis. In orthotopic mouse models using human pancreatic cancer cell lines, we found that
Hh target gene Gli1 is up-regulated during pancreatic cancer metastasis. Specific inhibition of Hh
ligand-mediated signaling significantly altered gene expression profiles in the tumor microenvironment
but had no significant effects on cancer metastasis. It is not known whether combining Smoothened
inhibitors with inhibitors targeting K-RAS downstream effectors will be effective in suppression of
pancreatic cancer metastasis. Both hedgehog signaling and K-RAS signaling are activated in pancreatic
cancer. While Hh ligand-mediated signaling is mainly activated in tumor microenvironment, K-RAS
is activated both in the cancer cells and in the tumor microenvironment. Targeting both pathways
may produce a synergistic inhibition on pancreatic cancer metastasis. We have further delineated the
mechanisms for the interactions between BMA833923 and AZD6144 using a variety of approaches.
2. Results
2.1. Effects of Hh Signaling on Metastatic Niche Gene Expression
We first used an orthotopic mouse model for pancreatic cancer metastasis to monitor gene
expression changes in the cancer cells and in the metastatic niche. Human MIA PaCa2 cells were used
to form tumors in the pancreas of immune deficient NSGtm mice, as initially established in Fidler’s
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laboratory and this model allows us to examine gene expression in the cancer cells (human gene
transcripts) as well as in the metastatic niche (mouse gene transcripts). We also used mouse pancreatic
cancer cells MMC18 [17] and Pan02 [18] in the metastatic models using immune competent C57/B6
mice for functional studies. In the metastasis mouse models, we ectopically expressed green fluorescent
protein (GFP) and luciferase in cancer cells before spleen injection of the mice. As shown previously,
these ectopically expressed proteins do not affect the metastatic characteristics and biology of pancreatic
cancer cells, and we can monitor tumor growth by luciferase activity and the site of metastasis by the
appearance of GFP expression [19]. We obtained the liver tissues with or without metastases for RNA
extraction and gene expression analyses by real-time PCR and RNA sequencing.
We detected a high level of mouse Gli1 transcript in the metastatic liver in comparison with that
in the primary tumors or lymph node metastasis (Figure 1A, p < 0.005). As a hedgehog signaling
target gene, high expression of Gli1 indicates hedgehog signaling activation [20]. We also detected
elevated human GLI1 gene expression (Figure S1), indicating activated Hh signaling in the pancreatic
cancer cells.
To identify the molecular mechanism underlying hedgehog signaling activation, we examined
expression of hedgehog ligands in the metastatic tumors as well as in the niche, and found elevated
expression of IHH in cancer cells of metastatic liver tissues (Figure 1B,C, p < 0.005), indicating that
inhibition of smoothened (e.g., BMS833923) may be effective in suppression of Hh signaling. Indeed,
we found that the gene expression pattern in mice with liver metastasis was altered by treatment
with smoothened inhibitor BMS833923 to resemble the gene expression pattern of the normal liver
(Figure 1D), indicating that Hh signaling is important for gene expression regulation in the host.
To determine the significance of Hh signaling for pancreatic cancer metastasis, we treated the
mice with pancreatic cancer metastasis with smoothened inhibitor BMS833923. After treatment,
we examined the mice for pancreatic tumors, and the number/size of metastatic nodules. While we
observed reduction of pancreatic tumor size (Figure 1E, p < 0.05), metastatic nodules were not
significantly affected (see Figure 1F for representative images). This is not surprising, and is
consistent with the failed clinical trial with smoothened inhibitors vismodegib [21,22] and saridegib [23]
in patients with metastatic pancreatic cancer.
Smoothened inhibitor BMS833923 mainly blocks Hh ligand-mediated signaling in tumor
microenvironment [19]. In contrast, K-RAS signaling is activated both in the pancreatic cancer cell and
in the tumor microenvironment. While the single agent BMS833923 was not effective in suppression
of pancreatic cancer metastasis, it is still possible that combining hedgehog signaling inhibition with
reduction of K-RAS signaling, the major driver for pancreatic cancer development, may be effective.
We have evidence to show that inhibition of K-RAS downstream effector MEK signaling by AZD6244,
but not the PI3K signaling by BEZ235, reduced Hh target gene GLI1 expression in pancreatic cancer
cells (Figure S2). We thus predict that combination of MEK inhibitor AZD6244 with Smoothened
inhibitor BMS833923 may be effective in suppressing pancreatic cancer metastasis.
2.2. Suppression of MEK/ERK and Hh Signaling Reduces Pancreatic Cancer Metastasis
While there are several mouse models for pancreatic cancer metastasis, therapeutic studies require
robust models to obtain data with sufficient power. We decided to use two models to test the effects
of combined MEK/Hh signaling inhibitors. First, orthotopic mouse models using human pancreatic
cancer cells in immune deficient mice are feasible for these studies, enabling us to determine the effects
of drugs on human cancer cells. Second, one commonly used model for liver metastasis of pancreatic
cancer is to inject cells into spleen, and to examine the number of metastatic nodules in the liver a few
weeks later [24–26]. For all mouse cell lines tested in the liver metastasis model, we observed liver
metastasis in all mice and the time of onset does not vary very much from mouse to mouse (e.g., ~20
days for MMC18 cell-based model). In contrast, several GEM models are not feasible for drug treatment
studies of metastasis. First, the metastasis onset and mouse survival time vary significantly from mouse
to mouse in several GEM models with spontaneous liver and lung metastasis, including the KPC
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model, Pdx1-cre/KRASG12D/p16F/F mice [14,17,27]. For example, KPC mice have metastasis onset
from 10 to 40 weeks (our unpublished observation and Hingorani et al. [14]), making it hard to compare
the number of metastatic nodules in different groups. Similarly, Pdx1-cre/KRASG12D/p16F/F [17]
mice have metastatic onset from 8 to 20 weeks (our observation and Qiu et al. [17]), and the power
for distinguishing the difference between the two groups requires more than 100 mice in each group,
which is not feasible. Second, pancreatic injection of mouse pancreatic cancer cell lines (KPC2, MMC18
and Pan02) leads to quick development of pancreatic tumors but rarely have liver and lung metastases.
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by Student t-test of two independent means (n = 5/group). (C) Western blotting analysis of IHH 
protein levels in tumors of pancreas, lymph nodes and liver. Metastatic nodules were dissected (based 
on GFP-expression) from liver tissues for protein analysis to reduce the Ihh protein level from the 
tumor microenvironment. We performed protein analysis from three independent mice with liver 
metastases and three normal liver tissues with similar results. (D) The effect of smoothened inhibitor 
BMS833923 on liver gene expression patterns in MIA PaCa2-based orthotopic mouse model was 
shown following RNA sequencing analyses. While metastatic liver tissues have a very different gene 
expression pattern from naïve liver tissues, addition of BMS833923 every the other day for 3 weeks 
altered the gene expression pattern to reassemble that of naïve liver tissues. (E) The effect of 
smoothened inhibitor BMS833923 on pancreatic cancer growth was revealed by weekly with 
bioluminescent intensity from the cancer cells as well as the tumor weight difference after the mice 
were sacrificed. Five mice per group were used in this experiment (with power 95% alpha error 0.05). 
(F) Whole body imaging detection of GFP expression pancreatic cancer cells in pancreas, lymph 
nodes, lung and liver in MIA Paca2-based orthotopic mouse model following administration of 
BMS833923 or with vehicle control. White arrows indicate the site of pancreatic cancer cells (GFP 
positive). Scale bar: centimeter. Similar results were also observed in AsPC1-based orthotopic mouse 
model (Figure S4 and S5). 
We first tested the effect of the combined treatment with MEK and Hh inhibitors in orthotopic 
mouse models using human cancer cells. MIA PaCa2 cells were used for orthotopic models in 
Figure 1. ctivated hedgehog signaling in orthotopic ouse odels of pancreatic cancer metastasis.
(A) Expression of ouse Gli1 gene, an indicator for hedgehog signaling activity, in tu or-bearing
pancreatic tissues, etastatic ly ph nodes and liver, was detected by Taq an-based real-ti e PCR
analysis. ** p < 0.005 by Student t-test of two independent means (n = 5/group). (B) The transcript
levels of SHH and IHH in different tissues were detected by real-time PCR (Taqman-based) ** p < 0.005
by Student t-test of two independent means (n = 5/group). (C) Western blotting analysis of IHH protein
levels in tumors of pancreas, lymph nodes and liver. Metastatic nodules were dissected (based on
GFP-expression) from liver tissues for protein analysis to reduce the Ihh protein level from the tumor
microenvironment. We performed protein analysis from three independent mice with liver metastases
and three normal liver tissues with similar results. (D) The effect of smoothened inhibitor BMS833923
on liver gene expression patterns in MIA PaCa2-based orthotopic mouse model was shown following
RNA sequencing analyses. While metastatic liver tissues have a very different gene expression pattern
from naïve liver tissues, addition of BMS833923 every the other day for 3 weeks altered the gene
expression pattern to reassemble that of naïve liver tissues. (E) The effect of smoothened inhibitor
BMS833923 on pancreatic cancer growth was revealed by weekly with bioluminescent intensity from
the cancer cells as well as the tumor weight difference after the mice were sacrificed. Five mice per
group were used in this experiment (with power 95% alpha error 0.05). (F) Whole body imaging
detection of GFP expression pancreatic cancer cells in pancreas, lymph nodes, lung and liver in MIA
Paca2-based orthotopic mouse model following administration of BMS833923 or with vehicle control.
White arrows indicate the site of pancreatic cancer cells (GFP positive). Scale bar: centimeter. Similar
results were also observed in AsPC1-based orthotopic mouse model (Figure S4 and S5).
We first tested the effect of the combined treatment with MEK and Hh inhibitors in orthotopic
mouse models using human cancer cells. MIA PaCa2 cells were used for orthotopic models in immune
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deficient NSG mice. Five days after pancreatic injection when microscopic metastasis is observed in
the liver (as indicated by GFP positive cells in intravital microscope images in Figure S3), we treated
mice with Hh inhibitor BMS833923, MEK inhibitor AZD6244, the combined treatment, or with PBS
control. As shown in Figure 2A, we found that the combined treatment led to a significant decrease in
the number of metastatic nodules in the liver (see Figure S4 for GFP positive nodules). We calculated
the number of mice with liver metastasis in different groups, and found that the mice treated with both
AZD6244 and BMS833923 had no or very few visible metastatic nodules whereas mice in other groups
all had over 10 metastatic nodules in the liver. In contrast to metastatic nodules, we did not observe
any synergy between AZD6244 and BMS833923 in reduction of tumor weight in this orthotopic model
(Figure S5). Similar results were also obtained using AsPC1 cells (Figure 2B). In addition, we found
that the lifespan in the double treatment group was significantly extended in the AsPC1-based mouse
model (Figure 2C). For MIA PaCa2 based model, mice can survive longer than 2 months without any
observed changes in survival for reasons we still do not understand. In summary of this experiment,
we observed a synergistic effect (as expressed in statistical term as a more than additive effect) between
BMS833923 and AZD6244 in two orthotopic mouse models.
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Figure 2. Simultaneous inhibition of MEK and Hh sig li i ouse models. (A) The number of
metasta ic nodules in the liver in MIA PaCa2-based ort del in immune deficient NSG mice
from f ur different treatments: (1) treated with smoot ibitor BMS8 3023; (2) treated with
MEK inhibitor AZD6244; (3) the combination of AZ 6 S8 3923; and (4) vehicle control (5)
mice/group); (B) Effect of different treatments on the nu ber of etastatic nodules in AsPC1-based
mouse model (5 mice/group); (C) Kaplan-Meier survival curve for mice with different treatments in
AsPC1-based mouse model, ** p < 0.05 was derived from Log-rank (Mantel-Cox) test; (D) Effect of
different treatments on liver tissue weight, a measurement for liver metastasis, in MMC18-based model
in immune-competent C57/B6 mice (5 mice/group). * p < 0.05 and ** p < 0.005 indicate significant or
synergistic effect by BLISS independence analysis (see Statistical analyses for details).
Next, we tested the effects of drug treatments using mouse cell line MMC18 in immune competent
mice [17,19]. We treated the mice 2 days after spleen injection when microscopic metastases are
detectable. This way, we can determine whether inhibition of MEK and Hh signaling is sufficient
to reduce an important step in metastasis, post-extravasation tumor growth (colonization). Due to
appearance of numerous metastatic nodules in the liver in this model (n > 100), we used liver weight
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as a way to measure the severity of liver metastasis instead, which has been previously used by
many other researchers [18,28,29]. We observed that the liver weight was reduced by the combined
treatment with MEK and Hh signaling inhibitors, and the effect was more than additive, suggestive
of a synergistic effect between BMS833923 and AZD6244 according to BLISS independent analysis
(see Methods for this analysis) in comparison with single treatments (Figure 2D). The compounds for
MEK and Hh signaling inhibition are very specific. For example, BMS833923 reduced the expression
of Gli1 over 90% (Figure S6A). Similarly, AZD6244 reduced the ERK phosphorylation significantly
(Figure S6C,D). These results indicate that inhibiting hedgehog and MEK signaling is sufficient to
reduce metastatic colonization of the cancer cells in the liver.
Taken together, our data indicate that simultaneous suppression of MEK and Hh signaling has a
more than additive effect on reduction of metastasis, particularly the post-extravasation tumor growth
of pancreatic cancer, whereas single agents have limited effects.
2.3. Effects of MEK Inhibitor AZD6244 and Smoothened Inhibitor BMS833923 on Cell Proliferation
The post-extravasation tumor growth of pancreatic cancer may be caused by increased cell
proliferation or decreased apoptosis (or cell death). Because we did not observe any significant changes
in the level of cleaved caspase 3 (an indicator for apoptosis) by combined treatment with AZD6244
and BMS833923, we turned our focus on regulation of cell proliferation by these two inhibitors. We
detected Ki-67 staining or EdU labeling to determine changes in cell proliferation. Because both
MEK signaling and the Hh pathway are known to regulate cell proliferation [30–33], we predict that
both AZD6244 and BMS833923 should reduce the rate of Ki-67 positivity. As shown in Figure 3A
(MIA PaCa2- based model), Ki-67 staining positivity in the untreated metastatic liver tumor was
27.57%. AZD6244 treatment reduced Ki-67 positivity to 19.13% whereas BMS833923 treatment resulted
in 21.51% Ki-67 positivity. Furthermore, combined treatment with AZD6244 and BMA833923 reduced
Ki-67 positivity to only 7.25%, which is significantly more effective than single treatments. According
to BLISS independence analysis, the effect from these two drugs is synergistic (more than additive
effect in statistical term, as indicated by ** in Figure 3). In contrast to the metastatic tissues, we did
not observe a synergistic effect between AZD6244 and BMS833923 in cell proliferation of the primary
pancreatic tumors (Figure 3B). We also observed a synergistic effect between AZD6244 and BMS833923
on reduction of Ki-67 positivity in AsPC1 and MMC18-based mouse models (Figure 3C,D).
To determine how MEK inhibitor AZD6244 can have a synergy with Smoothened inhibitor
BMS833923, we have performed gene expression analysis in metastatic tumor microenvironment.
As shown in Figure S7, we found that both MEK inhibitor AZD6244 and Smoothened inhibitor
BMS833923 affected gene expression in the metastatic niche. We further discovered that the top
three pathways affected were also shared by these two inhibitors, including leukocyte extravasation
signaling, agranulocyte adhesion and diapedesis, and hepatic fibrosis. These analyses indicate that
both BMS833923 and AZD6244 affect cell functions in the metastatic niche.
2.4. Effects of MEK Inhibitor AZD6244 and Smoothened Inhibitor BMS833923 on Cell Population at the
Metastatic Niche
We prepared single cells from metastatic tissues (mainly liver), and performed flow cytometry
analyses. We observed a significant increase in CD45+ cells, particularly Ly6G+ cells (Figure 4A and
Figure S8). We assessed whether the percentage of CD45 cells in the liver is regulated by MEK and Hh
signaling inhibitors. The number of CD45 cells in the metastatic liver was measured after treatment
with these two inhibitors by immunofluorescent staining (Figure 4A,B) and flow cytometry (Figure 4C).
As shown in Figure 4A,B, we found that the number of CD45+ cells was reduced by AZD6244 as
well as by BMS833923, and the combined treatment had a more significant reduction based on BLISS
independence analysis, as shown in Figure 4B [34]. We also confirmed this effect by flow cytometry
analysis (Figure 4C).
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immunofluorescent staini g images of CD45+ cells in liver tissues aft r drug treatments. (B) Summary of
A from 10 images in each gr up (fro at le st 3 mice) with the number of CD45+ cells per field under
micr scope (200×). (C) Summary of fl w cytometry analysis of CD45+ cells in different treatment groups
(from three mice/group). * indicates p < 0.05 and ** indicates a more than additive effect via BLISS
independence analysis.
Furthermore, we analyzed different populations in the CD45+ cells, and found that CD11b+Gr1+
cells (with majority of them Ly6G+CD11b+ cells) are the most common cell type in the metastatic
niche by flow cytometry analysis (Figure 5A,B) [35–37], suggesting that these cells may be critical
for metastatic colonization of pancreatic cancer cells. CD11b+Ly6G+ cells may be neutrophils or
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myeloid-derived suppressor cells (MDSC). Because both cell types have similar surface markers. It is
also possible that this is a mixed cell population of neutrophils and MDSC.
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Figure 5. Effects of MEK/Hh signaling inhibition on Ly6G+CD11b+ cells in the metastatic liver
tissues (MMC18-based model in immune competent C57/B6 mice). (A) Representative images of flow
cytometry of CD45+CD11b+Gr1+ cells in different liver tissues; (B) Cell population composition in
metastatic liver tissues, and the number was the average from five mice/group; (C) Representative
images of liver tissues with or without treatment of Ly6G neutralizing antibodies. While IgG
treated mice had many metastatic nodules (indicated by purple arrowheads), Ly6G neutralizing
antibody treatment led to no visible or only a few metastatic nodules; (D) Ly6G neutralizing antibody
treatment led to reduced liver weight in MMC18- based mouse model (five mice/group), suggesting a
reduced liver metastasis; (E) Similar results were obtained using Pan02 cells (five mice/group). Ly6G
neutralizing antibody treatment led to reduced liver weight. * p values were calculated using Student t
test of two independent means.
2.5. The Significance of Ly6G+CD11b+ Cells for Liver Metastasis of Pancreatic Cancer
We have evidence to show that Ly6G+CD11b+ cells are the cell population affected most by
combined treatment with BMS833923 and AZD6244 (Figure S9). To determine the significance of
Ly6G+CD11b+ cells for liver metastasis of pancreatic cancer, we used specific neutralizing antibodies
to deplete Ly6G+ cells in two mouse models: MMC18-based model through injection of matrix
gel-embedded cancer cells into spleen; Pan02 cells as another model [29,38,39]. The host mouse is
immune competent C57B/6. After cell injection, we treated mice with Ly6G neutralizing antibody
(clone 1A8) or the control IgG protein (see Methods for details). The effect of 1A8 IgG was assessed
by the appearance of the Ly6G+CD11b+ cell population after administration of antibodies. Reduction
of the CD11b+Gr1+ cell population by 70% with 1A8 IgG will indicate successful cell depletion
(Figure S10). We found that 3 out 4 mice treated with 1A8 IgG reduced the Ly6G+CD11b+ cell
population by 70% in the MMC18 mouse model. In the Pan02 mouse model, all mice treated with
1A8 IgG had reduced Ly6G+CD11b+ population by 70%. Four weeks after injection, we measured the
liver weight to show the severity of liver metastasis [18,28,29]. As shown in Figure 5 (Figure 5C,D),
Ly6G neutralizing antibody-treated mice had significantly reduced liver weights in comparison with
the control group. While depletion of immune cells does contribute to the reduced liver weight
(by ~10%), reduction of liver weight by ~50% indicates a major effect of Ly6G+CD11b+ cells on
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metastasis. We obtained similar results from Pan02-based model (Figure 5E). These results indicate
that Ly6G+CD11b+ cells are critical for liver metastasis of pancreatic cancer.
2.6. Stimulation of Cancer Cell Proliferation by Ly6G+CD11b+ Cells
The major feature of cancer cell colonization is an increase in proliferation of metastatic cancer cells.
Using Ki-67 positivity as a marker for cell proliferation, we found that MEK and Hh signaling inhibition
simultaneously reduces proliferation of the metastatic cancer cells in the mouse model (Figure 3).
Similarly, we investigated whether Ly6G neutralizing antibodies affect proliferation of metastatic
cancer cells, and we measured cell proliferation using Ki-67 staining in liver tissues treated with either
Ly6G neutralizing antibodies or the control IgG in the mouse models. As indicated in Figure 6A,
we found that Ki-67 positive cancer cells (K19+) was significantly reduced (p < 0.005). These data
indicate that the metastatic niche cells, such as Ly6G+ cells, can promote cancer cell proliferation.
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Figure 6. Regulation of cancer cell proliferation by inhibition of MEK and Hh signaling in mouse
models and in cultured cells. (A) Expression of Ki-67 was used as the readout of cell proliferation,
and percentage of Ki-67 positive cells in the metastatic cancer cells was calculated under microscope
from MMC18-based model in immune competent C57/B6 mice (five mice/group), * p value < 0.05.
These results are similar to those from MIA PaCa2-based model in immune deficient NSG mice
(see Figure 3A); (B) EdU incorporation of cancer cells in the presence or absence of Ly6G+CD11b+
cells in vitro. EdU incorporation of cancer cells was used to measure cell proliferation rate. With
an increase in Ly6G+CD11b+ cells (ratio 0:1; 1:1; 1:2 with increased number of Ly6G+CD11b+ cells),
EdU incorporation in the cancer cells was visualized (representative images shown above; summary
from 3 independent experiments shown below), scale: 400×; (C) Effects of different compounds
in reducing cell proliferation of cancer cells were assessed in vitro. Ly6G+CD11b+ cells were first
treated with different compounds for 2 h before adding to the top chamber. The data were from
three independent experiments. * indicates significant change (p < 0.05). While Ly6G+CD11b+ cells
significantly stimulated cell proliferation of cancer cells (* indicates p < 0.005), treatment with MEK
inhibitor AZD6244 (or Hh signaling inhibitor BMS833923) for 2 hours before being added onto the
top chamber significantly reduced cancer cell proliferation (p < 0.05). Combination of AZD6244 with
BMS833923 had a more than additive effect on cell proliferation (** indicates synergistic effect via BLISS
independent analysis).
To determine whether Ly6G+ cells promotes cancer cell proliferation through direct cell-cell
interaction or indirectly through secretion of growth factors, we used inserts to separate cancer
cells from Ly6G+CD11b+ cells. The pore size of the inserts was small enough (0.45 M) to prevent
Ly6G+CD11b+ cells from slipping through the pore. First, we tested EdU incorporation of cancer cells
in the presence of equal amount of Ly6G+CD11b+ cells, or at 2:1 and 4:1 ratio (Ly6G+CD11b+ cells
vs. cancer cells). As shown in Figure 6B, we found that a significant increase of the EdU incorporation
rate by addition of increased amount of Ly6G+CD11b+ cells, indicating that Ly6G+CD11b+ cells indeed
can stimulate cancer cell proliferation, and this effect was cell-contact independent.
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In the next experiment, we tested whether combination of AZD6244 and BMS833923 can
synergistically suppress cancer cell proliferation. Similar to the animal studies, we had four groups
of samples: BMS833923-treated group, AZD6244-treated group, the combined treatment group and
the untreated control. We found that while both drugs reduced the 5-ethynyl-2′-deoxyuridine (EdU)
incorporation rate of the cancer cells, the combined treatment group had a more than additive effect
on cancer cell proliferation (BLISS independence analysis), making the EdU incorporation rate nearly
back to the basal level (Figure 6C). These results are very similar to the animal studies, indicating
that Ly6G+CD11b+ cells are the major driving force for elevated cell proliferation of metastatic cancer
cells, which is essential for metastatic colonization of pancreatic cancer cells in the liver. These results
indicate that Ly6G+CD11b+ cells are critical for cell proliferation of the metastatic cancer cells, and this
effect requires MEK and Hh signaling.
In summary, we discovered that combined inhibition of Hh signaling and MEK signaling reduces
pancreatic cancer metastasis in mouse models. Simultaneous inhibition of these two signaling
pathways suppressed metastatic colonization of pancreatic cancer cells. We identified Ly6G+CD11b+
cells as the major cell population targeted by both pathways, and depletion of this population
significantly reduced colonization of pancreatic cancer cells in the liver. We further demonstrated
that Ly6G+CD11b+ cells are able to stimulate proliferation of cancer cells in vitro, and suppression of
MEK and Hh signaling synergistically reduced this effect. These results suggest that combination of
a smoothened inhibitor with a MEK inhibitor may be effective in clinical management of metastatic
pancreatic cancer.
3. Discussion
Progression and metastasis of pancreatic cancer is accompanied with numerous changes in the
cancer cells as well as in the metastatic niche, and mouse models have provided the means to study
the significance of these changes [9,10,40–46]. Alteration in the metastatic niche can also offer an
opportunity in novel therapeutics [47]. Our data have demonstrated that combining smoothened
inhibitor BMS833923 with MEK inhibitor AZD6244 is more effective in suppression of pancreatic
cancer metastasis, as indicated by reduced the number of metastatic nodules (Figure 2), a decrease in
cell proliferation (Figure 3) and reduced number of Ly6G+CD11b+ neutrophils (Figure S8). It appears
that MEK signaling regulates both cancer cells and the metastatic niche. We have further shown that
depletion of Ly6G+ cells is also effective in reducing the number of metastatic nodules (Figure 5).
These data provide a rationale to combine smoothened inhibitors with MEK inhibitors for clinical trials
in pancreatic cancer patients.
Although the molecular mechanism underlying Hh signaling activation in the metastatic niche
is currently not well characterized, our data suggest that elevated IHH expression in the metastatic
cancer cells may be responsible (Figure 1). We have shown both in the mouse model and in human
specimens that IHH is highly expressed in the metastatic cancer cells (Figure 1). If IHH is the major
driver for Hh signaling activation, neutralizing antibodies to IHH should be effective in suppressing
Hh signaling in the niche as well as liver metastasis of pancreatic cancer.
Ly6G+CD11b+ cells are major myeloid-derived immature cells, often with T-cell suppressive
effect. They could be neutrophils. This is the very cell population with the most significant change in
the metastatic niche in the mouse models, both in immune deficient mice and in immune competent
mice (Figure 5 and Figure S7). In our study, we found that this cell population has a significant
proliferation-promoting effect on cancer cells both in vitro co-culture experiment and in mice (Figure 6).
In immune competent mice, we also observed that depletion of Ly6G+/CD11b+ cells increases CD8+ T
cell population (Figure S8), consistent with a T-cell suppressing role. Thus, our studies indicate that
Ly6G+/CD11b+ cells are a cell population with multiple cellular functions. Due to their significant
changes in metastases, strategies to suppress their function in the human pancreatic cancer patients
will have a significant clinical implication on cancer treatment.
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We have shown that combination of smoothened inhibitor BMS833923 and MEK inhibitor
AZD6244 synergistically reduced liver colonization of pancreatic cancer cells. Colonization, described
as a process of the post-extravasation tumor growth, is a limiting step for metastasis. At present,
the exact factors driving tumor cell proliferation during colonization of pancreatic cancer remain to
be identified. Our evidence indicates that PDGF signaling is important for proliferation of metastatic
pancreatic cancer cells. PDGF signaling is a known signaling pathway involved in cancer cell
proliferation [48–52]. For example, we showed that purified Ly6G+/CD11b+ cells induce proliferation
of cancer cells (as indicated by an increase in EDU labeling) (Figure 5). When PDGF-A neutralizing
antibodies were used, the increase of cell proliferation in the cancer cells was significantly inhibited.
At the same time, addition of PDGF-A neutralizing antibodies alone had no effects on cancer cells,
suggesting that these neutralizing antibodies affect cancer cells through Ly6G+/CD11b+ cells. We also
noticed that PDGF-A neutralizing antibodies were not as effective as the combination of MEK/HH
inhibitors, indicating that PDGF-A is not the only factor stimulating cancer cell proliferation.
4. Materials and Methods
4.1. Chemicals
Hh signaling inhibitors BMS833923 was provided by Bristol–Myers Squibb (New York, NY, USA).
BMS833923 is a potent synthetic small molecule (EC50 = 50 nmol/L) with specific inhibition on
smoothened signaling (18). BMS833923 was originally patented by Exelixis (Alameda, CA, USA) and is
now licensed to Bristol–Myers Squibb. AZD6244 was purchased from the Selleckchem Chemicals LLC
(Houston, TX, USA).
4.2. Cell Lines
AsPC1 & MIA PaCa2 were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA), authenticated by STR profiling, and cultured as instructed by
the vendor. Pan02 was purchased from ATCC. All culture materials were purchased from Gibco/Life
Technology Inc., (Gibco, Grand Island, NY, USA). MMC18 cells, provided by Dr. Gloria Su, were
generated from metastatic tumors of mouse pancreatic cancer model [17], and cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS). AsPC1 was cultured in
RPMI1640 Medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin
and 100 mg/mL streptomycin. Other cell lines were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Grand Island, NY, USA),
100 U/mL penicillin and 100 mg/mL streptomycin. The cultures maintained in a humidified incubator
at 37 ◦C and 5% CO2.
4.3. Animals
NOD/SCID/IL2Rnull (NSG) female mice were provided by the In Vivo Therapeutics (IVT) Core
in the Simon Cancer Center at Indiana University School of Medicine. C57Bl/6 female mice were
purchased from Jackson laboratory. Use of animal was approved by the IACUC committee in Indiana
University School of Medicine (ethical code 11370; approval date—15 February 2018).
4.4. Orthotopic Mouse Model of Pancreatic Cancer Metastasis
AsPC-1 and MIA PaCa2 cells with stable expression of GFP and luciferase were harvested in single
cell suspension at a concentration of 4× 106 cells/ ml as described in a previous publication [19]. A total
of 2 × 105 cells (in 50 l of growth medium) were injected into pancreas of NSG mice using a 27-gauge
needle according to a protocol developed in Fidler’s laboratory [25]. C57/B6 mice were anesthetized
and spleens were exposed. Pan02 and MMC18 cells in 50 µL of growth factor-reduced Matrix gel
(BD Bioscience, San Jose, CA, USA) was injected into spleen to establish a liver metastasis model as
reported previously [18]. Drug treatment started five days after tumor inoculation. BMS-833923 was
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dissolved in acidified water (9.99 mL sterile water plus 10 uL 1N HCl) at concentration 7.5 mg/mL.
AZD6244 was suspended in sterile PBS by sonication at 5 mg/mL. For drug treatment, mice were
treated with BMS-833923 (oral gavage at 15 mg/Kg body weight daily), AZD6244 (oral gavage
10 mg/kg daily) or corresponding control vehicles in each group. More precise tumor location
and tumor size were confirmed. After mouse was dissected, tumor weight was measured and
metastatic tumors were located. Tumor lesions in pancreas, liver, lung and lymph nodes were
harvested and divided into several portions. One portion was snap-frozen in liquid nitrogen for
mRNA extraction; some were fixed in 10% buffered formalin and embedded in paraffin for H&E
staining and immunohistochemistry; others fixed in zinc fixative buffer and embedded in paraffin for
immunofluorescence staining of CD45.
4.5. Depletion of Ly6G+ Cells
Rat anti-Ly6G (1A8) antibody and control Rat IgG were generously given by Dr. Jie Sun. Mice
received 50µg either anti-Ly6G antibody or control IgG in PBS in a volume of 200µL injected
intraperitoneally beginning on the same day of cancer cells inoculation and continuing twice a week
throughout the study.
4.6. Quantification of Metastatic Burden
The number of visible lymph node, liver and lung metastases was determined with aid of whole
body imaging, and lung metastases were also confirmed microscopically. Metastatic nodules on liver
surface were counted macroscopically in MIA PaCa2 injected mice as previously reported [53,54].
It was counted as 100 if the number of metastatic nodules is above 100. In Pan02 and MMC18 injected
mice, metastatic foci are difficult to be counted due to tumor immergence, so liver weight was used as
an indicator to evaluate metastatic burden [18].
4.7. Single Cell Isolation
Using a 21-blade scalpel, mince the tumor-containing liver tissues into the smallest possible
fragments (less than 1 mm3) and place the tumor into 50 mL conical tube containing 10 mL collagenase
IV (Worthington, Lakewood, NJ, USA) solution at a concentration of 1 mg/mL. Place the tube(s)
into a 37 ◦C water bath with shaking for 1–1.5 h, agitating with a 10-mL pipette every 20 min to
augment digestion. Then the digested tumor solution was strained through a sterile 70-µm cell strainer
(BD Falcon, San Jose, CA, USA), and the resulting cell solution was collected and washed 3 times
followed by cell number counting and antibody labeling for flow cytometry.
4.8. Immunohistochemistry (IHC) and Immunofluorescence (IF)
Fresh tissue was harvested and fixed with 10% buffered-formalin or zinc-based fixative [24], which
was used for surface marker staining of infiltrated blood cells in tissue, such as CD45. Five-micron
paraffin-embedded sections were labeled with primary antibodies against phosphor-p44/p42 MAPK
(Erk1/2) (Thr 202/Tyr 204) (Cell Signaling Technology Cat# 4370, 1:200, Danvers, MA, USA), Ki-67 (ab15580,
1:500, AbCam, Cambridge, MA, USA) and CD45 (14-0451, 1:100, eBioscience, San Diego, CA, USA).
4.9. Flow Cytometry
Single cells from primary and metastatic tumors were incubated with fluorescence conjugated
antibody against mouse CD45, Ly6G, CD11b, Ly6C, F4/80 (Biolegend, San Diego, CA, USA) for 30 min
in 4 ◦C. After washed, cells were stained with 1ug/ml DAPI for discrimination of dead cells.
Flow cytometry was performed on a LSR407 device (Beckton Dickinson, Franklin Lakes, NJ, USA)
and data analyzed using flowjo software. For cell sorting, stained cells were sorted on a BD FACSAria
(BD, San Jose, CA, USA) according to the fluorescent colors used.
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4.10. Cell Proliferation Assay
Cell proliferation assay was performed in a double chamber co-culture system. MIA PaCa2 or
MMC18 cells were seeded in 24-well plate with cover slip at the density of 20,000 cells/well. Next day,
cells were starved DMEM medium containing 0.5% FBS for 6 hours before co-cultured with sorted
neutrophils. CD45+CD11b+Ly6G+ cells sorted from metastatic tumor bearing liver were seeded in
the upper chamber (0.4 um transwell) at different ration to cancer cells in 0.5% FBS DMEM for 24 h.
2 h before collection of the cancer cells, ethynyl-2-deoxyuridine (EdU) was added in lower chamber
at 5 uM final concentration. Edu incorporated into DNA was detected according to the protocol of
the manufacturer (Click-iT® EdU Alexa Fluor® 594 Imaging Kit; Invitrogen, Carlsbad, CA, USA).
To evaluate cell proliferation in vivo, mice were injected with EdU intraperitoneally at 40 mg/kg,
4 h before being sacrificed. We visualized the incorporation of EdU on tissue slides to identify cells
undergoing DNA replication as previously reported [55].
4.11. RNA Extraction, RT-PCR and Real-Time PCR
Total RNAs of cells were extracted using Tri-RNA reagent from Sigma according to the
manufacturer’s instruction and 1 µg of total RNA was reverse transcribed into cDNAs using the
first-strand synthesis kit (Roche, Tucson, AZ, USA). Real-time quantitative PCR analyses were
performed according to a previously published procedure. Triplicate CT values were analyzed
in Microsoft Excel using the comparative Ct(∆∆Ct) method as described by the manufacturer
(Applied Biosystems, Foster City, CA, USA). The amount of target (2−∆∆Ct) was obtained by
normalization to an endogenous reference (Gapdh for mice and GAPDH for humans) and relative to
a calibrator. All taqman primers and probes were purchased from Applied Biosystems Inc. and the
catalog numbers are shown below (Table 1):
Table 1. Real-time PCR probe information.
Human SHH HS00179843
Human IHH HS01081800
Mouse Gli1 Mm00494654
Mouse Ptch1 Mm00436026
Human GLI1 Hs01110766
4.12. RNA-seq, Sequence Alignment, Differential Expression Analyses
For transcriptomic analysis, total RNAs were extracted using TRIzol Reagent (Invitrogen), and the
RNA quality in each specimen assured by the Agilent bioanalyzer profiles before moving on to cDNA
synthesis and library construction. Sequencing was conducted using SOLiD 5500 with 75 bp in one
direction. Analyzing process was conducted as the normal bioinformatics analyzing method. The RNA
abundance was evaluated by Reads per kilobases per million reads (RPKM). All sequenced libraries
were mapped to the mouse genome and human genome separately (UCSC mm9, hg19) using LifeScope
2.5 with the default parameters. The reads distribution across the genome was assessed using bamutils
(from ngsutils) [56]. Sequencing reads which can be uniquely mapped to either genome with mapping
quality >8 were kept for further analysis. Reads that mapped to each genome were assigned to mm9
refGene and hg19 refGene genes respectively. Genes with read count per million (CPM) < 1 in more
than half of the samples were removed. The data was normalized using TMM (trimmed mean of M
values) method. Differential expression analysis was performed using edgeR with generalized linear
model [57,58]. False discovery rate (FDR) was computed from p-values using the Benjamini-Hochberg
procedure. The ingenuity pathway analysis (IPA) was performed on genes that significantly (adjusted
p-value < 0.05) differentially expressed between two groups.
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4.13. Western Blot Analysis
Aspc1 cells bearing tumor tissue from pancreas, lymph node and liver was lysed in cell lysis
buffer (50 mM Hepes, pH 7.4, 2 mM EDTA, 100 mM NaCl, 1% Glycerol, 1% Triton X-100) containing
protease and phosphatase inhibitors (Roche). Added 200 µL of ice-cold lysis buffer per 10 mg tissue
and homogenized with an electric homogenizer on ice. After centrifuge, supernatant was used for
analysis. After separation by 8% or 10% SDS-polyacrylamide gel electrophoresis and protein transfer
onto PVDF membrane. Expression of proteins was detected using the following antibodies: IHH
(AbCam, ab39634, 1:500, Cambridge, MA, USA); phosphor-p44/p42 MAPK (Erk1/2) (Thr 202/Tyr 204)
(Cell Signaling Cat# 9101, 1:1000, Danvers, MA, USA). Protein loading was assessed by the presence of
total p44/p42 MAPK (Erk1/2) (Cat# 9102, 1:1000, Cell Signaling Technology Inc., Danvers, MA, USA)
and beta-actin (Cat# A5441, 1:10,000, Sigma, St. Luis, MO, USA).
4.14. Statistical Methods
Data are presented as mean ± SD from at least three independent experiments. Statistical
comparisons between two groups were performed using a two-tail unpaired t-test with p values of
<0.05 indicating statistically significant difference. Survival data were analyzed using the Kaplan-Meier
method with a log-rank (Mantel-Cox) test for comparison of survival curves. For animal studies, power
analysis was performed to adjust the number of mice in each study. In general, we used sufficient
animal number to obtain at least 80% power with 0.05 alpha error. For example, in the liver metastasis
model, we predicted 50% of reduction in liver weight following treatment with Ly6G neutralizing
antibodies. To obtain 95% power with 0.05 alpha error, we will need 3 mice in each experimental group.
Synergistic effects between two drugs was calculated with Bliss independence analysis as previously
reported [19]. In brief, if drug a and drug b have additive effects (independent effects), the observed
effect (Yab-O) should be the same as predicted (Yab-p = Ya + Yb − Ya × Yb). Yab-p is the predicted effect
of the combined use of drugs a and b, and Yab-O is the observed effect of the combined use of drug
a and drug b. Ya is suppression fraction by drug a, and Yb is the suppression fraction for drug b.
A more than additive effect (as synergistic effect) is predicted if Yab-O is bigger than Yab-p. In contrast,
antagonistic effect is predicted if Yab-O is smaller than Yab-p.
5. Conclusions
In conclusion, we found that combination of hedgehog (Hh) and MEK signaling inhibitors reduces
pancreatic cancer metastasis in mouse models. In mouse models of pancreatic cancer metastasis,
specific inhibition of smoothened signaling significantly altered the gene expression profile in the tumor
microenvironment but had no significant effects on cancer metastasis. By combining Hh signaling
inhibitor BMS833923 with RAS downstream MEK signaling inhibitor AZD6244, we observed reduced
number of metastatic nodules in several mouse models. These two inhibitors also decreased cell
proliferation significantly and reduced CD45+ cells (particularly Ly6G+CD11b+ cells). We demonstrated
that depleting Ly6G+CD11b+ cells is sufficient to reduce cancer cell proliferation and the number of
metastatic nodules. In vitro, Ly6G+ CD11b+ cells can stimulate cancer cell proliferation, and this effect
is sensitive to MEK and Hh inhibition. Our results suggest that combination of smoothened inhibitor
BMS833923 and MEK inhibitor AZD6244 may be effective in reducing pancreatic cancer metastasis.
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Liver), Figure S2: Effects of K-RAS downstream signaling inhibitors on GLI1 expression in cancer cells, Figure S3.
Detection of microscopic and macroscopic metastases by intravital microscope, Figure S4: Whole body fluorescent
images of GFP-expressing AsPC1 cancer cells in mice with different treatments, Figure S5: Primary tumor
weight in different treatment groups, Figure S6: Effects of AZD6244 and BMs833923 on target protein expression,
Figure S7: Gene expression analysis of metastatic niche, Figure S8: Cell population analyses of metastatic liver
tissues, Figure S9: Cell population changes by MEK/Hh signaling inhibition, Figure S10: Effects of 1A8 on Ly6G
cell population.
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